Hepatitis C virus - related cryoglobulinemic vasculitis with renal involvement current possibilities of diagnostic and treatment


Cite item

Full Text

Abstract

The extrahepatic manifestations of HCV infections, which include mixed cryoglobulinemia (MC), are important for prognosis and determination of the treatment options of these patients. Currently, mixed MC type II is considered as a specific marker of chronic HCV infection. Kidney damage is one of the severe, often determining a prognosis of extrahepatic manifestation of HCV-associated cryoglobulinemic vasculitis. The review discusses the current diagnostic approaches to cryoglobulinemic GN, as well as perspectives for improving antiviral and pathogenetic therapy.

About the authors

S. Yu Milovanova

Sechenov First Moscow State Medical University (Sechenov University)

д.м.н., в.н.с. НИО здоровьесберегающих технологий Научно-технологического парка биомедицины; тел: +7(903)143-50-50; e-mail: sveta@milovanova.ru; ORCID: 0000-0002-2687-6161 Moscow, Russia

L. V Kozlovskaya(Lysenko)

Sechenov First Moscow State Medical University (Sechenov University)

д.м.н., проф. каф. внутренних, профессиональных болезней и ревматологии медико-профилактического факультета; ORCID: 0000-0002-1166-7308 Moscow, Russia

L. Yu Milovanova

Sechenov First Moscow State Medical University (Sechenov University)

д.м.н., проф. каф. внутренних, профессиональных болезней и ревматологии медико-профилактического факультета; ORCID: 0000-0002-5599-0350 Moscow, Russia

N. B Gordovskaya

Sechenov First Moscow State Medical University (Sechenov University)

к.м.н., доц. каф. внутренних, профессиональных болезней и ревматологии медико-профилактического факультета Moscow, Russia

T. M Ignatova

Sechenov First Moscow State Medical University (Sechenov University)

д.м.н., в.н.с. НИО здоровьесберегающих технологий Научно-технологического парка биомедицины Moscow, Russia

M. V Taranova

Sechenov First Moscow State Medical University (Sechenov University)

к.м.н., доц. каф. внутренних, профессиональных болезней и ревматологии медико-профилактического факультета; ORCID: 0000-0002-7363-6195 Moscow, Russia

T. V Androsova

Sechenov First Moscow State Medical University (Sechenov University)

к.м.н., доц. каф. внутренних, профессиональных болезней и ревматологии медико-профилактического факультета Moscow, Russia

References

  1. Gorevic P.D, Kassab H.J, Levo Y, et al. Mixed cryoglobulinemia: Clinical aspects and long - term follow - up of 40 patients. Am J Med. 1980;69:287-308. PMID: 6996482
  2. Meltzer M, Franklin E.C, Elisa K, et al. Cryoglobulinemia - a clinical and laboratory study. II. Cryoglobulins with rheumatoid factor activity. Am J Med. 1966;40:837-56. PMID: 4956871
  3. Brouet J.C, Clouvel J.P, Danon F, et al. Biologic and clinical significance of cryoglobulins. Am J Med. 1974;57:775-88. PMID: 4216269
  4. Agnello V, Romain P.L. Mixed cryoglobulinemia secondary to hepatitis C virus infection. Reum Dis Clin North Am. 1996;22(1):1-21. PMID: 8907062
  5. Ferri C, Mascia M.T. Cryoglobulinemic vasculitis: Review. Curr Opin Rheumatol. 2006;18:54-63. PMID: 4216269
  6. D’Amico G. Renal involvement in hepatitis С infection: Cryoglobulinemic glomerulonephritis. Kidney Int. 1998;54:650-87. PMID: 9690235
  7. Charles E.D, Dustin L.B. Hepatitis C virus induced cryoglobulinemia. Kidney Int. 2009;76(8):818-24. doi: 10.1038/ki.2009.247
  8. Ferri C. Mixed cryoglobulinemia. Orphanet J Rare. 2008;3:25. doi: 10.1186/1750-1172-3-25
  9. Тэгай С.В., Лопаткина Т.Н., Косминкова Е.Н., Козловская Л.В. Поражение почек, ассоциированное с вирусами гепатитов В и С. Consilium Med. 2002;4(7):337-41.
  10. Saadoun D, Landau D.A, Calabrese L.H, Cacoub P. Hepatitis C-associated mixed cryoglobulinemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology. 2007;46:1234-42. doi: 10.1093/rheumatology/kem132
  11. Милованова С.Ю., Игнатова Т.М., Козловская Л.В. Особенности течения хронического гепатита С с криоглобулинемией. Клиническая гепатология. 2006;2(1):15-8.
  12. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis c. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999;42:2204-12. doi: 10.1002/1529-0131
  13. Mc Guire B.M, Julian B.A, Bynon J.S, et al. Brief communication: Glomerulonephritis in patients with hepatitis C cirrhosis undergoing liver transplantation. Ann Intern Med. 2006;144:735-41. PMID: 16702589
  14. Arase Y, Ikeda K, Murashima N, et al. Glomerulonephritis in autopsy cases with hepatitis C virus infection. Intern Med. 1998;37:836-40. doi: 10.2169/internalmedicine.37.836
  15. Jonson R.J, Gretch D.R, Couser W.G, et al. Hepatitis C virus - associated glomerulonephritis. Effect of α-interferon therapy. Kidney Int. 1994;46:1700-4. PMID: 7535369
  16. Trejo O, Ramos-Casals M, Garcia-Carrasco M. Cryoglobulinemia: study of etiologic factors and clinical and immunologic in 443 patients fr om a simple center. Medicine. 2001;8:252-62. PMID: 11470986
  17. Cacoub P, Delluc A, Saadoun D, et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vaskulitis: wh ere do we stand? Ann Rheum Dis. 2008;67(3):283-7. doi: 10.1136/ard.2006.065565
  18. Ferri C, Sebastiani M, Antonelli A, et al. Current treatment of hepatitis C-associated rheumatic diseases. Arthritis Res Ther. 2012;14:215-21. doi: 10.1186/ar3865
  19. Милованова С.Ю., Лысенко (Козловская) Л.В., Милованова Л.Ю., Мрыхин Н.Н., Русских А.В. HCV-ассоциированная смешанная криоглобулинемия и В-клеточная неходжкинская лимфома - патогенетически связанные проблемы. Терапевтический архив. 2018;(6):112-21. doi: 10.26442/terarkh2018906112-120
  20. Игнатова Т.М., Козловская Л.В., Гордовская Н.Б., Чернова О.А., Милованова С.Ю., Новиков П.И., Некрасова Т.П., Бекетова Т.В., Мухин Н.А. Криоглобулинемический васкулит, ассоциированный с вирусом гепатита С: 20-летний опыт лечения. Терапевтический архив. 2017;89(5):46-52. doi: 10.17116/terarkh201789546-52
  21. Emery J.S, Kuczynsky M, La D, et al. Efficacy and safety of direct acting antiviral for the treatment of mixed cryoglobulinemia. Am J Gastroenterol. 2017;112:1298-308. doi: 10.1038/ajg.2017.49
  22. Saadoun D, Pol S, Ferfar Y, et al. Efficacy and safety of sofosbuvir plus daclatasvir for treatment of HCV-associated cryoglobulinemia vasculitis. Gastroenterol Hepatol. 2017;15:575-83. doi: 10.1053/j.gastro.2017.03.006
  23. Gragnani L, Piluso A, Urraro T, et al. Virological and clinical response to interferon - free regimens in patients with HCV-related mixed cryoglobulinemia:preliminary results of a prospective pilot study. Curr Drug Targets. 2017;18:772-85. doi: 10.2174/1389450117666160208145432
  24. Jean-Michel Pawlotsky, Alessio Aghemo, Geoffrey Dusheiko, Xavier Forns, Massimo Puoti, Christophe Sarrazin. EASL Recommendations on Treatment of Hepatitis C 2018. European Association for the Study of the Liver (EASL). doi: 10.1016/j.jhep.2018.03.026
  25. Executive summary of the 2018 KDIGO hepatitis C in CKD Guideline: welcoming advances in evaluation and management. Kidney Int. 2018;94:663-73. doi: 10.1016/j.kisu.2018.06.001
  26. Saxena V, Koraishy F.M, Sise M.E, et al. Safety and efficacy of sofosbuvir - containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36:807-16. doi: 10.1111/liv.13102
  27. Nazario H.E, Ndungu M, Modi A.A. Sofosbuvir and simeprevir in hepatitis C genotype 1 - patients with end - stage renal disease on haemodialysis or GFR<30 ml/min. Liver Int. 2016;36:798-801. doi: 10.1111/liv.13025
  28. Li T, Qu Y, Guo Y, Wang L. Efficacy and safety of direct acting antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: A meta - analysis. Liver Int. 2016;37:974-81. doi: 10.1111/liv.13336
  29. Comarmond C, Garrido M, Pol S, et al. Direct - acting antiviral therapy restores immune tolerance to patients with hepatitis C virus - induced cryoglobulinemia vasculitis. Gastroenterology. 2017;152:2052-62. doi: 10.1053/j.gastro.2017;02.037
  30. Sise M.E, Bloom A.K, Wisocky J, Chung R.T. Treatment of Hepatitis C Virus-Associated Mixed Cryoglobulinemia with Sofosbuvir-Based Direct-Acting Antiviral Agents. Hepatology. 2015;63:408-17. doi: 10.1002/hep.28297
  31. Rutlenge S.M, Chung R.T, Sise M.E. Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis. Hemodialysis Int. 2018;22:81-96. doi: 10.1111/hdi.12649
  32. Cornella S.L, Stine J.G, Kelly V, Caldwell S.H, Shah N.L. Persistence of mixed cryoglobulinemia despitecure of hepatitis C with new oral antiviral therapyincluding direct - acting antiviral sofosbuvir: A caseseries. Postgrad Med. 2015;127:413-7.
  33. Saadoun D, Thibault V, Ahmed S.N.S, et al. Sofosbuvir plus ribavirin for hepatitis C virus - associated cryoglo - bulinaemia vasculitis: VASCUVALDIC study. Ann Rheum Dis. 2015;75:1777-82.
  34. Cacoub P, Ahmed S.A, Ferfar Y, Pol S, et al. long - term efficacy of interferon - tree antiviral treatment regimens in patients with hepatitis C virus - associated cryoglobulinemia vasculitis. Clin Gastroenterol Hepatol. 2019;17:518-26. doi: 10.1016/j.cgh.2018.05.021
  35. Landau D, Saadoun D, Halfon P, et al. Relapse of hepatitis C virus - associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum. 2008;58(2):604-11. doi: 10.1002/art.23305
  36. Giannini C, Petrarca A, Monti M, et al. Associated between persistent lymphatic infection by hepatitis C virus after antiviral treatment and mixed cryoglobulinemia. Blood. 2008;111:2943-5. doi: 10.1182/blood-2007-09-112490

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies